Suchergebnisse - "Safra, Tamar"

PubPharm (7)

1

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

enthalten in: British journal of cancer | 2018

von Friedlander, M. | Matulonis, U. | Gourley, C. | +18

2

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy : an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

enthalten in: The Lancet. Oncology | 2016

von Ledermann, J. | Harter, P. | Gourley, C. | +15

CommentIn: Lancet Oncol. 2016 Nov;17 (11):1474-1475. - PMID 27819228

3

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

enthalten in: British journal of cancer | 2016

von Ledermann, J. | Harter, P. | Gourley, C. | +14

4

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation : Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

enthalten in: Cancer | 2016

von Matulonis, U. | Harter, P. | Gourley, C. | +13

5

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

enthalten in: The Lancet. Oncology | 2014

von Ledermann, J. | Harter, P. | Gourley, C. | +15

CommentIn: Lancet Oncol. 2014 Jul;15(8):783-5. - PMID 24882435

6

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer

enthalten in: The New England journal of medicine | 2012

von Ledermann, J. | Harter, P. | Gourley, C. | +12

CommentIn: N Engl J Med. 2012 Jul 12;367(2):179; author reply 179-80. - PMID 22784123

7

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2012

von Kaye, S. | Lubinski, J. | Matulonis, U. | +13

CommentIn: J Clin Oncol. 2012 Feb 1;30(4):347-50. - PMID 22203759

1
[1]